Policy & Regulation

BCI trial participants publish their own recommendations for how trials should be run

When Ian Burkhart’s brain implant study at Ohio State began winding down over funding, he told STAT, the review board overseeing it suggested the device be taken out and another put in if the money came back. “That’s great when it’s not you that’s going through experimental brain surgery,” he said.

Burkhart received his implant in 2014 and later founded the BCI Pioneers Coalition, a group led by people who have taken part in implanted brain-computer interface trials. On 10 November the coalition published OUR BCI, its recommendations for how those trials should be designed, run and ended. They are addressed to investigators, sponsors, manufacturers, funders, institutions, research ethics boards and regulators, and cover 13 areas, from access to trial information and consent to brain data and care after a trial. The coalition calls the document a first step toward a code of practice and encourages the field to work toward a binding code that review boards, research funders and regulators can use for oversight. For now the recommendations have no legal force.

What the recommendations ask for

Non-disclosure agreements should be precise, negotiated before a participant consents, and limited in time. No agreement should stop a participant from raising safety, rights or misconduct concerns with healthcare providers, lawyers, regulators, ethics bodies, safety monitors or family, and the document calls for that exception to be impossible to waive. Participants should not be penalised for disclosing something by accident.

Before surgery, the agreements should say who legally owns each part of the system: the implanted components, the external hardware, accessories, the software, access credentials, decoders built for the individual participant, and replacement parts. A sponsor’s or manufacturer’s property interest should not on its own decide whether an implant is removed, switched off or made unusable.

Brain data should be treated as the participant’s personal information, with researchers acting as its stewards. Participants keep a right of access to their own data, any limits on their use of it should be set out at consent, and new uses beyond the original agreement should need their approval.

Participants should not pay out of pocket to take part, and should be paid for their time beyond expenses, including when they appear at events that publicise a research programme or a manufacturer.

When a trial ends, the document asks for device updates and maintenance for “a reasonable time period”, with funders setting money aside for it. It suggests an escrow fund to pay for removing the implant, so participants can choose when and where that happens, plans for whether participants can follow the researchers if the trial moves to another institution, and that researchers and manufacturers aim for devices that keep basic functions working for as long as possible, even if a company stops supporting them.

Who wrote it

The recommendations came out of facilitated video discussions between October 2025 and October 2026 with members of the coalition. Burkhart developed the project with Amanda van Beinum, a sociologist at York University, and Jennifer Chandler, Canada Research Chair in the Law and Ethics of Brain Technologies at the University of Ottawa, under a Partnership Engage Grant from Canada’s Social Sciences and Humanities Research Council. The academics led the process and drafted the text with a core group of participants. Burkhart, Galen Buckwalter, Scott Imbrie and Buz Chmielewski are listed as the participant leads.

The document reflects the views of six coalition members and says so. It calls itself a living statement that cannot represent everyone who might use an implant, and the coalition plans to review it every 24 months.

Industry and ethics voices

Florian Solzbacher, co-founder and chairman of Blackrock Neurotech, whose Utah array was used in Burkhart’s implant, told The Debrief that participants should understand how their information is collected, used and protected. He said neural data covers different things, from recordings used, and possibly needed, to run a device to data used for separate research questions, and that each purpose should be clear at consent. Blackrock is listed as one of the coalition’s project partners.

On long-term support, the ethicist Anna Wexler said on a panel at a recent industry conference in New York that the field has no good solution yet. “We talk about potentially mandatory insurance policies, escrows, and institutions committing support, but right now we just don’t actually have solutions,” she said, STAT reported.

Signal: Why it matters

STAT describes the field as moving from a niche, proof-of-concept phase into a startup ecosystem with eager investors and multiple clinical trials. In that setting the recommendations could add costs for sponsors and funders that do not already budget for post-trial maintenance, an escrow for removal surgery or pay for participants’ time, and limits on non-disclosure agreements and clear ownership terms would need to be settled in trial agreements before consent.

The document asks for devices that are “robust against commercial discontinuation”. An approved implant has already shown the alternative: Second Sight discontinued its Argus II retinal implant in 2019 and nearly went out of business in 2020, and IEEE Spectrum reported in 2022 that more than 350 blind people around the world were left with implants the company no longer supported. Trials also pause. WIRED reported this month, and Synchron confirmed, that the company had voluntarily paused enrolment in trials of its second-generation Stentrode over a performance problem with the lead, with devices already implanted in some participants. Synchron says no device-related safety issues have been found, that it will resume after upgrading the system, and that it will support participants with Stentrode devices across their lifetime.

Researchers have raised the same point. In September, four researchers from Mayo Clinic, University College London and Sichuan University named long-term support for study participants as one of four ethical priorities for implant research in Nature Neuroscience.

Not disclosed

How long “a reasonable time period” of post-trial support should be, or what it would cost. Who would fund an escrow for implant removal: the sponsor, the institution or the research funder. The document does not name all six contributors or the trials they took part in. Whether any company, hospital or review board has adopted the recommendations.

Forward Radar: What to watch

Whether any implant company publishes a post-trial support or removal commitment that matches the document.

Whether review boards, research funders or the FDA refer to it in trial requirements or guidance.

The coalition’s first scheduled review, planned 24 months after publication, and whether it adds participants from other trials and devices.

Sources

Primary:

Coverage:

Cross-reference to prior InsideBCI coverage:

Weekly BCI Brief in your inbox

Join researchers, investors, and industry leaders who start their day with Inside BCI.